CLINICAL TRIALS IN CANCER:
A PATIENT AND FAMILY GUIDE
Clinical trials give patients access to the treatments that will become tomorrow's standard of care โ today. For patients who have exhausted standard options, a trial may be the most promising path forward.
analyticsAt a Glance
- check_circleThe experimental drug or device in a trial is provided free to eligible patients
- check_circlePhase I, II, and III trials serve different purposes โ understanding which you're entering matters
- check_circleMolecular profile (NGS) determines which trials you are eligible for
- check_circleCancerFax performs systematic trial matching based on your diagnosis and treatment history
What Is a Clinical Trial and Why Do They Exist?
Every cancer treatment currently approved was once an experimental agent tested in a clinical trial. Trials are the mechanism by which the medical community determines whether a new treatment is safe and effective โ and patients who participate are the essential link between laboratory discovery and clinical reality.
โClinical trials are not a last resort โ they are a clinical pathway. For many cancer patients, the most promising treatment available is not in any pharmacy yet. It is in a trial recruiting today.โ
How New Treatments Reach Patients
New cancer agents are tested in cell cultures and animal models (preclinical). Promising results lead to Phase I trials (safety in humans). Positive Phase I data leads to Phase II (efficacy and dose). Phase II success leads to Phase III (comparison to current standard). Regulatory approval follows positive Phase III. This process typically takes 8โ15 years โ trial participants access treatments a decade before they become standard.
Who Benefits from Trials
Trial participants receive access to treatments not available outside the study. Many trials cover trial treatment costs; some cover monitoring and study-related tests. Participants also receive closer medical monitoring than standard care โ additional MRI scans, blood tests, and specialist reviews. Future patients benefit from the evidence the trial generates.
Clinical Trial Phases: What Each One Means
Understanding which phase of trial you are entering is essential โ the purpose, risk profile, and what you can realistically expect from participation differs significantly.
| Phase | Primary Question | Typical Size | What to Expect | Benefit Likelihood |
|---|---|---|---|---|
| Phase I | Is this safe? What is the right dose? | 10โ50 patients | Dose escalation; multiple safety monitoring visits; you may be at a very early dose level | Low โ primary goal is safety, not efficacy; some patients do respond |
| Phase I/II | Safe and at what dose? Does it work? | 30โ100 patients | Combined safety + early efficacy; dose expansion cohorts for responsive tumour types | Low-moderate โ early signals of activity |
| Phase II | Does it work at the safe dose? | 50โ300 patients | Single arm or small randomised; response rate and PFS are primary endpoints | Moderate โ treatments reaching Phase II have passed safety; question is whether they are effective |
| Phase III | Is it better than the current standard? | 300โ3,000+ patients | Randomised (often blinded); you may receive current standard of care (control arm) or new treatment | Equal or better than standard โ most Phase III trials set current standard as control |
| Phase IV (post-approval) | How does it perform in real-world use? | Thousands of patients | Approved treatment monitored for long-term effects, rare adverse events | Benefit established โ this is already approved therapy |
How Clinical Trial Eligibility Is Determined
Each clinical trial has a specific set of inclusion and exclusion criteria โ these are not arbitrary bureaucratic hurdles. They define the patient population in which the experimental treatment is being evaluated.
Common Inclusion Criteria
Confirmed histological diagnosis (specific tumour type and grade); specific molecular markers (MGMT methylation, EGFR mutation, IDH status, PD-L1 expression, TMB โ determined by NGS); number and type of prior treatment lines; adequate performance status (ECOG 0โ2 in most trials); adequate organ function (liver, kidneys, bone marrow); and measurable disease by imaging criteria.
Common Exclusion Criteria
Prior treatment with the same drug class being tested; active brain metastases (in some trials); uncontrolled infection or autoimmune disease; pregnancy or breastfeeding; active second malignancy; specific organ dysfunction thresholds; and prior toxicity from related agents that the trial drug may reproduce.
How to Find and Join a Clinical Trial
The process from identifying a potentially suitable trial to becoming enrolled typically takes 2โ6 weeks โ understanding each step removes the intimidation factor.
- 1
Step 1: Complete Your Molecular Profile
Most cancer trials in 2024โ2025 require an NGS (next-generation sequencing) panel to identify molecular eligibility criteria. If you have not had comprehensive tumour genomic profiling, this should be done before or alongside trial matching. CancerFax can identify appropriate testing laboratories and ensure your profile covers the markers most commonly screened in trials for your cancer type.
- 2
Step 2: Trial Matching Based on Your Profile
CancerFax performs systematic matching of your diagnosis, molecular profile, and prior treatment history against open trial databases (ClinicalTrials.gov, Chinese National Registry, and proprietary data). We identify trials you are potentially eligible for โ not just trials in your cancer type, but specifically matched to your biomarker and treatment history.
- 3
Step 3: Pre-Screening Review
CancerFax submits your clinical summary to the trial site's principal investigator team for pre-screening review. The team confirms whether your records suggest eligibility before you commit to travel or a formal screening visit.
- 4
Step 4: Formal Screening Visit
If pre-screening is positive, you attend the trial site for formal eligibility assessment โ blood tests, imaging review, ECOG assessment, and consent. Approximately 20โ40% of patients who reach formal screening are found ineligible due to criteria not identifiable from records alone.
- 5
Step 5: Enrolment and Treatment
Following eligibility confirmation and informed consent, you are enrolled. The trial schedule โ visit frequency, treatment cycles, monitoring โ is explained in full by the trial team. CancerFax remains your case manager throughout trial participation, coordinating between you, the trial site, and your home oncologist.
Clinical Trial Myths vs Facts
Misconceptions about clinical trials prevent patients from accessing potentially beneficial treatment. Here we address the most common ones directly.
What Patients Often Believe
- "I'll be a guinea pig"Implies uninformed experimentation without consent or protection
- "Clinical trials are only for people who have no other options"Many patients wait too long before considering trials โ often past eligibility criteria
- "The control arm gets a placebo and nothing else"Concern about receiving no treatment
- "I have to stay near the trial site for the entire duration"Assumption that international trial participation is not possible
What Is Actually True
- Participants are protected by informed consent, ethics boards, and safety monitoring committeesTrial participants consent to everything they receive โ participation is always voluntary and can be withdrawn
- Trials are available at every disease stage โ many require only 1โ2 prior lines of therapyPatients who join trials earlier often have more options โ molecular eligibility criteria narrow over time as cancer evolves
- In oncology, control arms receive the current best standard of care โ not a placeboPure placebo controls are ethically impermissible when a standard of care exists โ you receive at minimum the current approved treatment
- Many trials accommodate remote or reduced-frequency visits after initial cyclesCancerFax coordinates visit schedules and remote monitoring for international patients in Asian cancer trials
Related Clinical Trial Resources
Specific trial access guides for brain and other cancer types.
Frequently Asked Questions
Cancer Clinical Trials
Do I have to pay for treatment in a clinical trial?
The experimental drug or device being tested is provided free of charge to enrolled participants โ this is a fundamental principle of clinical research, regardless of whether the trial is industry-sponsored or academic. Standard-of-care treatments you receive as part of the control arm or alongside the experimental drug may still be billed through normal healthcare channels. Study-specific monitoring tests (additional blood draws, PET scans, biopsies required by the protocol) are typically covered by the trial sponsor. Travel and accommodation costs for trial visits are usually patient-funded, though some trials provide travel support or financial assistance. CancerFax clarifies the full cost structure for each specific trial before you commit.
Can I withdraw from a clinical trial once I have started?
Yes โ you can withdraw from a clinical trial at any time, for any reason, without consequence to your ongoing medical care. Informed consent for trial participation explicitly includes the right of withdrawal without penalty. Your clinical care team โ and CancerFax as your case manager โ will support the transition back to standard-of-care treatment if you withdraw. Withdrawal does not affect your eligibility for future trials.
How does CancerFax perform clinical trial matching?
CancerFax uses a systematic approach: your molecular profile (NGS results), diagnostic pathology, prior treatment history, current disease status, and performance status are compared against open trial listings from global registries and our institutional partner networks in China and India. We identify trials for which you meet key eligibility criteria (molecular markers, prior treatment lines, organ function range) and present matched options with an explanation of why each trial is relevant. Pre-screening submission to trial sites is coordinated by CancerFax, and we advise on the visit schedule and logistics for trials where physical presence in China or India is required.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If a Clinical Trial Is Right for Your Case?
Upload your NGS report, pathology, and treatment history. CancerFax will perform systematic trial matching and identify open studies in China or India that match your molecular profile.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.